Retail Health Growth (H2 FY26)
40%+
+10pp vs industry
Retail health growth exceeded industry average of ~30% in H2 FY26, driven by GST tailwind.
NIVABUPAHEALTHINSURANCE
Financial Services
24 Apr 2026
Niva Bupa Health Insurance Co Ltd — Q4 FY26
Niva Bupa delivered a strong Q4 FY26 with GWP growth of 27.4% to ₹9,433 crore, driven by retail health growth of 35% and market share expansion to 10.4% in Q4.
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Niva Bupa delivered a strong Q4 FY26 with GWP growth of 27.4% to ₹9,433 crore, driven by retail health growth of 35% and market share expansion to 10.4% in Q4. PAT surged 80% to ₹366 crore, with combined ratio improving 160 bps to 101.4% on operating leverage. Management guided for sustained retail industry growth of 17-19% CAGR and expects combined ratio to reach ~99% by FY29, with expense ratio savings offsetting modest loss ratio uptick. Key risks include potential commission cap regulation and competitive pressure from GST-driven volume growth normalization.
Key Numbers
Market Share (Retail Health, Q4 FY26)
10.4%
+1.4pp YoY
Market share in retail health increased from 9.0% in Q4 FY25 to 10.4% in Q4 FY26.
Expense of Management Ratio (FY26)
33.7%
-550bps YoY
EoM ratio improved from 39.2% in FY25 to 33.7% in FY26 due to operating leverage.
Solvency Ratio
2.49x
flat YoY
Solvency ratio remained healthy at 2.49x as of March 2026, well above regulatory minimum.
Management Guidance
Combined ratio target of ~99% by FY29
Management expects combined ratio to improve to ~99% by FY29, driven by expense ratio savings of 200-250 bps.
Management guidance marginsRetail health industry growth of 17-19% CAGR over 5 years
Management reiterated view that retail health industry will grow at 17-19% CAGR over a 5-year horizon.
Management guidance growthLoss ratio may inch up by ~150 bps
Management guided that loss ratio may increase by about 150 bps over time, offset by expense ratio improvements.
Management guidance marginsKey Risks
Potential commission cap regulation
Regulatory changes could cap commission rates, impacting distribution costs and growth. Management awaits clarity but believes single expense limit is preferable.
high · analyst_questionNormalization of GST-driven growth
Industry growth may moderate as the GST tailwind fades. Management expects stabilization at 17-19% CAGR, but near-term volatility is possible.
medium · analyst_questionGroup health loss ratio volatility
Group health loss ratio was ~60.5% for FY26, and IFRS loss components on onerous contracts could signal underwriting risk.
medium · data_observationNotable Quotes
Our combined ratio for FY26 improved by 160 basis points to 101.4%.
Our retail health growth for the same period was in excess of 40%.
Our model says combined operating ratio should be let's say 99% or so in FY29.
Frequently Asked Questions
What was Niva Bupa Health's revenue in Q4 FY26?
Niva Bupa Health reported revenue of ₹9,433 Cr in Q4 FY26, representing a +27.4% change compared to the same quarter last year.
What guidance did Niva Bupa Health management give for FY27?
Combined ratio target of ~99% by FY29: Management expects combined ratio to improve to ~99% by FY29, driven by expense ratio savings of 200-250 bps. Retail health industry growth of 17-19% CAGR over 5 years: Management reiterated view that retail health industry will grow at 17-19% CAGR over a 5-year horizon. Loss ratio may inch up by ~150 bps: Management guided that loss ratio may increase by about 150 bps over time, offset by expense ratio improvements.
What are the key risks for Niva Bupa Health in FY27?
Key risks include Potential commission cap regulation — Regulatory changes could cap commission rates, impacting distribution costs and growth. Management awaits clarity but believes single expense limit is preferable.; Normalization of GST-driven growth — Industry growth may moderate as the GST tailwind fades. Management expects stabilization at 17-19% CAGR, but near-term volatility is possible.; Group health loss ratio volatility — Group health loss ratio was ~60.5% for FY26, and IFRS loss components on onerous contracts could signal underwriting risk..
Did Niva Bupa Health meet its previous quarter's guidance?
Scorecard data is being built as historical quarters are processed.
Where can I read the full Niva Bupa Health Q4 FY26 concall transcript?
The full earnings conference call transcript or source release is available on the linked source material. This page provides an AI-generated summary with filing verification status shown on the financial stats.